About NervGen Pharma

NervGen Pharma Corp. engages in the discovery, development and commercialization of pharmaceutical products for the treatment of nerve damage, including spinal cord injuries multiple sclerosis and Alzheimer’s disease. The company’s primary product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries, multiple sclerosis, and Alzheimer's disease. The company is developing NVG-291 and other PTPs receptor antagonists and may be developing other early stage preclinical and discovery drug candidates pursuant to the license agreement with CWRU and potentially others. The company has a licensing agreement with Case Western Reserve granting a license (the License) to it to use certain licensed technology (the Technology). The License allows the company to research, develop and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The License provides NervGen with an exclusive, worldwide right to use the Technology relating to leukocyte-common antigen related (LAR) family function blocking peptides in diseases and injuries and applications thereof to research, develop, make, have made, use, dispose and import licensed products for all applications. The License also grants NervGen the right to use, develop and commercialize the Technology for all diseases and medical conditions including, but not limited to, spinal cord injury, peripheral nerve injury, multiple sclerosis, Alzheimer’s disease, stroke and acute myocardial ischemia. History NervGen Pharma Corp. was incorporated in 2017.